By Katie Shaw, Senior Director, Patient Recruitment & Enablement, IQVIA
Kelly Sanford, Global Head of Site Operations, IQVIA Decentralized Trials, and
Mark Mentzer, Director, IQVIA Connected Devices
The COVID-19 pandemic has redefined the relationship between patients, technology and clinical research. When healthcare centers shut down, sponsors relied on decentralized clinical trial (DCT) models to keep patients and staff safe, while continuing to move research forward. In making this transition they discovered additional benefits of DCTs that take patient preferences and needs into consideration and include connected devices to drive greater efficiency and engagement.